NYSE:DOCS
Doximity, Inc.
A premier digital membership platform for healthcare professionals offering networking, credentialing, and clinical trial services.
Key Metrics
Investment Thesis
Bull Case
The stock offers compelling growth potential as the healthcare digital transformation accelerates and adoption of clinical trial services expands rapidly. Strong free cash flow generation allows for significant share repurchases totaling $120.3M, supporting earnings per share expansion without dilution. The network effect within the physician community creates a sustainable competitive barrier that protects long-term pricing power.
Bear Case
Valuation multiples may be stretched given the high growth expectations embedded in the current stock price compared to historical peers. Regulatory uncertainty surrounding clinical trial services poses an existential risk to one of the fastest-growing revenue segments. The company carries a retained earnings deficit of $186.9M which requires monitoring for future capital needs or potential equity dilution.
About Doximity, Inc.
Doximity (NYSE: DOCS) is a leading digital membership platform connecting healthcare professionals with trusted information and services. The company primarily serves physicians and other medical practitioners across the United States through its professional networking and credentialing solutions. Revenue growth has been driven by expansion in clinical trial services, patient care management tools, and advertising within its verified community.
Analysis
Management Discussion
Operating cash flow of $273.3M significantly exceeded net income of $223.2M, indicating strong working capital management and non-cash adjustments like share-based compensation of $72.4M. Revenue accelerated to $570.4M in 2025 from $419.1M in 2023, demonstrating a robust CAGR while net profit tripled to $223.2M from $112.8M two years prior.
Industry Overview
The healthcare technology sector is experiencing rapid consolidation and digital adoption, particularly in telehealth and clinical trial management where regulatory clarity is improving. Competition intensifies as large tech firms enter the space, but specialized platforms like Doximity retain advantages through deep domain expertise and verified networks. Market size continues to expand as value-based care models require better connectivity between payers, providers, and patients.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $419.1M | $475.4M | $570.4M |
| Cost of Revenue | $53.5M | $50.7M | $55.9M |
| Gross Profit | $365.6M | $424.8M | $514.5M |
| Operating Expenses | $240.5M | $260.9M | $286.7M |
| Operating Income | $125.1M | $163.9M | $227.8M |
| R&D | $80.2M | $82.0M | $93.0M |
| G&A | $36.7M | $37.8M | $45.7M |
| Marketing | $123.5M | $133.1M | $145.7M |
| Stock-Based Comp | $47.8M | $51.1M | $72.4M |
| D&A | $10.3M | $10.3M | $10.7M |
| Depreciation | $5.5M | $5.7M | $6.4M |
| Amortization | $4.8M | $4.6M | $4.3M |
| Other OpEx | $0 | $7.9M | $2.3M |
| Non-Operating Income | $8.0M | $21.3M | $35.8M |
| Pre-Tax Income | $133.2M | $185.2M | $263.6M |
| Income Tax | $20.3M | $37.6M | $40.4M |
| Continuing Ops | $112.8M | $147.6M | $223.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $112.8M | $147.6M | $223.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $112.8M | $147.6M | $223.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $975.5M | $912.9M | $1.09B |
| Cash & Equivalents | $158.0M | $96.8M | $209.6M |
| Accounts Receivable | $107.0M | $101.3M | $128.4M |
| Prepaid Expenses | $22.3M | $48.7M | $44.6M |
| Other Current Assets | $688.1M | $666.1M | $706.0M |
| Long-Term Assets | $161.4M | $166.4M | $175.7M |
| PP&E (Net) | $11.3M | $12.3M | $13.7M |
| Goodwill | $67.9M | $67.9M | $67.9M |
| Operating Leases | $13.8M | $12.3M | $8.9M |
| Other LT Assets | $68.4M | $73.8M | $85.2M |
| Total Assets | $1.14B | $1.08B | $1.26B |
| Current Liabilities | $139.5M | $147.2M | $156.3M |
| Accounts Payable | $1.3M | $2.3M | $1.4M |
| Current Leases | $1.8M | $2.1M | $2.2M |
| Deferred Revenue | $105.2M | $99.1M | $114.3M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $31.3M | $30.7M | $25.4M |
| LT Operating Leases | $13.9M | $12.4M | $10.2M |
| Other LT Liab | $17.2M | $18.1M | $15.0M |
| Total Liabilities | $170.8M | $178.0M | $181.7M |
| Shareholders' Equity | $966.1M | $901.4M | $1.08B |
| Paid-In Capital | $762.1M | $823.9M | $894.2M |
| Retained Earnings | $217.9M | $80.0M | $186.9M |
| AOCI | $-14.1M | $-2.7M | $1.3M |
| Total L&E | $1.14B | $1.08B | $1.26B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $112.8M | $147.6M | $223.2M |
| Non-Cash Adjustments | $20.0M | $19.4M | $13.2M |
| Working Capital Changes | $46.8M | $17.1M | $36.8M |
| Cash from Operations | $179.6M | $184.1M | $273.3M |
| Capital Expenditures | $1.7M | $147.0K | $0 |
| Cash from Investing | $-59.9M | $31.2M | $-29.3M |
| Share Buybacks | $85.3M | $280.7M | $120.3M |
| Cash from Financing | $-74.5M | $-276.5M | $-131.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $45.2M | $-61.2M | $112.8M |
| Beginning Cash | $112.8M | $158.0M | $96.8M |
| Ending Cash | $158.0M | $96.8M | $209.6M |
Frequently Asked Questions
How does Doximity, Inc. make money?
The company's revenue streams include Professional Membership subscriptions, Clinical Trial Services connecting sponsors with verified physicians, Patient Care Management solutions for health systems, and Advertising services leveraging its trusted medical community.
What are the main risks for DOCS?
Regulatory headwinds from state medical boards that may restrict access to clinical trial recruitment or impose compliance burdens. Dependence on third-party payers and advertising clients which could lead to margin pressure if pricing power erodes. Potential disruption from alternative telehealth platforms or changes in reimbursement models affecting patient care management tools.
What is DOCS's competitive advantage?
Doximity possesses a deep moat through its exclusive network of over 4 million US healthcare professionals who verify credentials in real-time. The platform benefits from high switching costs as physicians build their professional identity and patient connections within the ecosystem. Its verified data set provides unique insights for pharmaceutical sponsors and health systems, creating a defensible data advantage.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.